MedPath

ZELBORAF

These highlights do not include all the information needed to use ZELBORAF safely and effectively. See full prescribing information for ZELBORAF. ZELBORAF (vemurafenib) tablet for oral use Initial U.S. Approval: 2011

Approved
Approval ID

38eea320-7e0c-485a-bc30-98c3c45e2763

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Nov 27, 2023

Manufacturers
FDA

Genentech, Inc.

DUNS: 080129000

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Vemurafenib

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code50242-090
Application NumberNDA202429
Product Classification
M
Marketing Category
C73594
G
Generic Name
Vemurafenib
Product Specifications
Route of AdministrationORAL
Effective DateNovember 27, 2023
FDA Product Classification

INGREDIENTS (9)

VEMURAFENIBActive
Quantity: 240 mg in 1 1
Code: 207SMY3FQT
Classification: ACTIB
CROSCARMELLOSE SODIUMInactive
Code: M28OL1HH48
Classification: IACT
HYDROXYPROPYL CELLULOSE (90000 WAMW)Inactive
Code: UKE75GEA7F
Classification: IACT
HYPROMELLOSE ACETATE SUCCINATE 16070722 (3 MPA.S)Inactive
Code: 24P2YXD2PW
Classification: IACT
TITANIUM DIOXIDEInactive
Code: 15FIX9V2JP
Classification: IACT
POLYETHYLENE GLYCOL 3350Inactive
Code: G2M7P15E5P
Classification: IACT
TALCInactive
Code: 7SEV7J4R1U
Classification: IACT
FERRIC OXIDE REDInactive
Code: 1K09F3G675
Classification: IACT
POLYVINYL ALCOHOL, UNSPECIFIEDInactive
Code: 532B59J990
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.